Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Roche’s SARS-CoV-2 Test Receives EUA | Contract Pharma

What are you searching for?

Sign in
Breaking News

Roche’s SARS-CoV-2 Test Receives EUA

First commercial test for SARS-CoV-2 will enable expedited coronavirus testing with results in three and half hours

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

U.S. FDA has issued an Emergency Use Authorization (EUA) for Roche’s cobas SARS-CoV-2 Test. It is intended for the detection of SARS-CoV-2, the virus that causes COVID-19 disease, in swab samples from patients who meet COVID-19 clinical criteria for testing. Hospitals and reference labs can run the test on Roche’s automated cobas 6800 and cobas 8800 Systems, which are widely available in the U.S. and around the world.

The cobas 6800/8800 Systems provide test results in three and half hours with up to 96 results and in about three hours and a total of 1,440 results, respectively.  

Upon authorization, Roche will have millions of tests a month available for use on the cobas 6800 and 8800 systems.  

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters